University of Pennsylvania

Novartis Ag

Saar Gill

Carl H June

Jennifer Brogdon

Marco Ruella

Michael Klichinsky

Andreas Loew

Ming Lei

Lu Huang

Jimin Zhang

David Jonathan Glass

Joan Mannick

Leon Murphy

Michael C Milone

Qilong Wu

Barbara Brannetti

David L Porter

Jiquan Zhang

Yongqiang Wang

Boris Engels

Jennifer Bordeaux

Brian Walter Granda

Li Zhou

Daniel J Powell

John Scholler

Michael D Kalos

Carla Guimaraes

Avery D Posey

Marcela V Maus

Thomas Huber

John C Byrd

Anna Vulpetti

Na Li

Saad Kenderian

Naveen Kumar Dakappagari

Ju Young Kim

Thai Tran

Hans Bitter

Elena Orlando

Regina M Young

Steven Highfill

Miriam Kim

Reshma Singh

Aimee S Payne

Hilmar Erhard Ebersbach

Huijuan Song

Mariusz Wasik

Natarajan Muthusamy

Celeste Richardson

Jan J Melenhorst

Lai Wei

Amy Jo Johnson

Daniela Angst

Qiumei Yang

Julia Jascur

Jason A Dubovsky

William Raj Sellers

Carla Patricia Pinto Guimaraes

Jonathan Hogan

Baomei Wang

Joseph Fraietta

Adam David Cohen

Eric Lancaster

Simon Lacey

Alex Ganetsky

Alfred Garfall

Pamela Shaw

David Teachey

Joseph A Fraietta

François Gessier

Jennifer Mary Bordeaux

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias

The present invention provides compositions and methods for transducing cells (e.g. T cells or immune cells). Also provided herein are methods of treating a disease in a subject in need thereof.

Methods and composition for gene delivery using an engineered viral particle

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.

Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells

Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain

The present invention relates to compositions and methods of generating modified hematopoietic stem or progenitor cells. One aspect of the invention includes a modified hematopoietic stem or progenitor cell comprising a nucleic acid capable of decreasing expression of an endogenous gene or a portion thereof, wherein the endogenous gene encodes a polypeptide comprising an antigen domain targeted by a chimeric antigen receptor (CAR). Another aspect of the invention includes a method for generating a modified hematopoietic stem or progenitor cell. Also included are methods and pharmaceutical compositions comprising the modified cell for adoptive therapy and treating a condition, such as an autoimmune disease or cancer.

Methods and compositions for gene editing in hematopoietic stem cells

The present disclosure relates to the identification and use of biomarkers (e.g., analytes, analyte profiles, or markers (e.g., gene expression and/or protein expression profiles)) with clinical relevance to cytokine release syndrome (CRS).

Biomarkers predictive of cytokine release syndrome

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Treatment of cancer using a CD123 chimeric antigen receptor

The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

Growing community of inventors

Philadelphia, PA, United States of America

Saar Gill